Zumaya GE, Quiroz MRA, Torres DAA, Medel BT

Language: Spanish
References: 16
Page: 379-387
PDF size: 309.94 Kb.

ABSTRACT

Background: Leukocytoclastic vasculitis is mediated by a type III hypersensitivity reaction. This entity is the most common vasculitis in clinical practice and is associated with a wide spectrum of conditions: autoimmune, neoplasms, infections, or drug hypersensitivity. Leukocytoclastic vasculitis is an infrequent manifestation of hypersensitivity to drugs; pharmacodermias only cause between 10 and 24% of cases; the most common causative agents are nonsteroidal anti-inflammatory drugs, beta-lactam antibiotics, or sulfa drugs. Clinically it manifests as palpable purpura that predominates in the lower extremities and trauma sites. Treatment focuses on symptom control, low-dose corticosteroids, or colchicine. When the cause is a medication, the prognosis is favorable and the suspension of the causative drug is usually healing.
Clinical case: Case 1: A 31-year-old male patient who presented, after consuming ketorolac, a dermatosis of both legs with purpuric spots and blisters with a necrotic center, that subsided after 5 days. Case 2: A 45-year-old male patient who manifested purpuric spots and blisters 12 hours after consuming naproxen.
Conclusions: Nonsteroidal anti-inflammatory drugs can potentially precipitate leukocytoclastic vasculitis, and early diagnosis and treatment reduce morbidity in adults.

REFERENCES

1. Fraticelli P, Benfaremo D, Gabrielli A. Diagnosis and managementof leukocytoclastic vasculitis. Intern Emerg Med 2021; 16 (4): 831-841. doi: 10.1007/s11739-021-02688-x

2. Mericliler M, Shnawa A, Al-Qaysi D, Fleisher J, Moraco A.Oxacillin-induced leukocytoclastic vasculitis. IDCases 2019;17: e00539. doi: 10.1016/j.idcr.2019.e00539

3. Fiorillo G, Pancetti S, Cortese A, Toso F, et al. Leukocytoclasticvasculitis (cutaneous small-vessel vasculitis) afterCOVID-19 vaccination. J Autoimmun 2022; 127: 102783.doi: 10.1016/j.jaut.2021.102783

4. Martín Guerra JM, Martín Asenjo M, Prieto de Paula JM.Vasculitis leucocitoclástica y linfoma [Leucocitoclasticvasculitis and lymphoma]. Rev Esp Geriatr Gerontol 2020; 55 (3): 182-183. doi: 10.1016/j.regg.2019.08.004

5. Brown K, Martin J, Zito S. Severe leukocytoclastic vasculitissecondary to the use of a naproxen and requiring amputation:a case report. J Med Case Reports 2010; 4: 204.https://doi.org/10.1186/1752-1947-4-204

6. Plaza Santos R, Jaquotot Herranz M, Froilán Torres C, PozaCordón J, et al. Vasculitis leucocitoclástica asociada a enfermedadde Crohn [Leukocytoclastic vasculitis associatedwith Crohn's disease]. Gastroenterol Hepatol 2010; 33 (6):433-5. doi: 10.1016/j.gastrohep.2009.07.004

7. Koutkia P, Mylonakis E, Rounds S, Erickson A. Leucocytoclasticvasculitis: an update for the clinician. Scand J Rheumatol2001; 30 (6): 315-22. doi: 10.1080/030097401317148499

8. Bouiller K, Audia S, Devilliers H, Collet E, et al. Etiologiesand prognostic factors of leukocytoclastic vasculitis withskin involvement: a retrospective study in 112 patients.Med (United States) 2016; 95 (28): e4238.

9. Landeta-Sa AP, Jaramillo-Manzur C, Medina-Castillo DE,Zequera-Valdez AK, Rodríguez-Patiño G. Leukocytoclasticvasculitis secondary to methotrexate: Case presentationand literature revision. Int J Cutaneous Disorders Med2019; 2 (1): 180008.

10. Naidu RP. Causality assessment: a brief insight into practicesin pharmaceutical industry. Perspect Clin Res 2013; 4 (4):233-6. doi:http://dx. doi.org/10.4103/2229-3485.120173

11. Goeser MR, Laniozs V, Wetter DA. A practical approach tothe diagnosis, evaluation, and management of cutaneoussmall vessel vasculitis. Am J Clin Dermatol 2014; 15 (4):299-306. doi: 10.1007/s40257-014-0076-6

12. Aounallah A, Arouss A, Ghariani N, Saidi W, et al. Vascularitescutanées leucocytoclasiques: à propos de 85cas. Pan African Medical J 2017; 26: 138. doi:10.11604/pamj.2017.26.138.9721

13. Khetan P, Sethuraman G, Khaitan B, Shama, V, et al. Anaetiological and clinicopathological study on cutaneousvasculitis. Indian J Med Res 2012; 135 (1): 107-113. DOI:https://dx.doi.org/10.4103%2F0971-5916.93432

14. Ouni B, Fathallah N, Ben-Sayed N, Slim R, et al. Enalaprillercanidipinecombination induced leukocytoclasticvasculitis: A case report. Br J Clin Pharmacol 2021; 87 (1):210-211. doi: 10.1111/bcp.14346

15. Garrote A, Bonet R. El papel de los AINE en el tratamientoanalgésico. Rev Offarm 2003; 22: 56-62.

16. Rawlings CR, Fremlin GA, Nash J, Harding K. A rheumatologyperspective on cutaneous vasculitis: assessmentand investigation for the nonrheumatologist. Int WoundJ 2015; 13 (1): 17-21.